| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.06.23 | S&P Dow Jones Indices: Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 | 457 | PR Newswire | NEW YORK, June 2, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open... ► Artikel lesen | |
| 03.06.23 | Replimune Group Inc: Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting | 547 | GlobeNewswire (Europe) | Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no progression... ► Artikel lesen | |
| 03.06.23 | Sutro Biopharma, Inc.: Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1 | 562 | GlobeNewswire (Europe) | - Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating... ► Artikel lesen | |
| 03.06.23 | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) | 717 | GlobeNewswire (Europe) | - Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable... ► Artikel lesen | |
| 03.06.23 | NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 | 624 | GlobeNewswire (Europe) | - Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate... ► Artikel lesen | |
| 03.06.23 | Affimed N.V.: Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan | 797 | GlobeNewswire (Europe) | Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC) cohortAFM24 showed clinical activity in 7 out of 15 heavily pre-treated... ► Artikel lesen | |
| 03.06.23 | Allogene Therapeutics, Inc.: Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting | 488 | GlobeNewswire (Europe) | Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation... ► Artikel lesen | |
| 03.06.23 | Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting | 277 | GlobeNewswire (Europe) | - Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma... ► Artikel lesen | |
| 03.06.23 | Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting | 594 | GlobeNewswire (Europe) | ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had tumor biomarker reduction (77%) with 32% having complete clearanceRobust... ► Artikel lesen | |
| 03.06.23 | Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023 | 294 | GlobeNewswire (Europe) | Zevra is a corporate sponsor of the Hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the... ► Artikel lesen | |
| 03.06.23 | Immunocore Holdings Limited: Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO | 1.958 | GlobeNewswire (Europe) | Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3 June... ► Artikel lesen | |
| 03.06.23 | Kayne Anderson Energy Infrastructure Fund, Inc.: Kayne Anderson Energy Infrastructure Fund Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at May 31, 2023 | 372 | GlobeNewswire (Europe) | HOUSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the "Company") (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced... ► Artikel lesen | |
| 03.06.23 | Kayne Anderson NextGen Energy & Infrastructure, Inc.: Kayne Anderson NextGen Energy & Infrastructure Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at May 31, 2023 | 151 | GlobeNewswire (Europe) | HOUSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Kayne Anderson NextGen Energy & Infrastructure, Inc. (the "Fund") (NYSE: KMF) today provided a summary unaudited statement of assets and liabilities and... ► Artikel lesen | |
| 03.06.23 | Echo-Spekulationsblase an der US-Börse | 252 | Claus Vogt | * Sehr bearishe Divergenzen * Spekulative Exzesse an der NASDAQ * Gold und Rohstoffe im Verhältnis zu Aktien extrem unterbewertet Liebe Leser,wie von uns prognostiziert, befindet sich die deutsche Wirtschaft... ► Artikel lesen | |
| 03.06.23 | Leipzig erlebt zweite Gewaltnacht in Folge | 2.416 | dts Nachrichtenagentur | Leipzig - Leipzig erlebt eine zweite Gewaltnacht in Folge. Auch am Samstagabend lieferten sich Linke und Polizei wieder Scharmützel im Stadtteil Connewitz. Bereits am Nachmittag hatte es Zusammenstöße... ► Artikel lesen | |
| 03.06.23 | Evaxion Biotech: Evaxion's AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial | 853 | GlobeNewswire (Europe) | The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality... ► Artikel lesen | |
| 03.06.23 | Erdogan vereidigt - Ökonom Mehmet Simsek wird Finanzminister | 2.543 | dts Nachrichtenagentur | Ankara - Der türkische Präsident Recep Tayyip Erdogan hat nach seiner Vereidigung am Samstag sein neues Kabinett vorgestellt - und dabei für einige Überraschungen gesorgt. Der erst 2018 von Erdogan... ► Artikel lesen | |
| 03.06.23 | Scharfe Korrektur bei Uniper, Amazon werkelt angeblich an eigenem Mobilfunkangebot und setzt damit die Deutsche Telekom unter Druck und Nel ASA bleibt zum Wochenende auf niedrigem Niveau | 4.905 | NTG24.de | Die Einigung im US-Schuldenstreit sowie eher durchwachsene Arbeitsmarktdaten aus Übersee waren vielleicht absehbar und führten zu einer spürbaren Erholung der Märkte. Kurz vor dem Wochenende gab es... ► Artikel lesen | |
| 03.06.23 | EQS-DD: Vulcan Energy Resources Limited: Skelton Family Trust, Kauf | 2.862 | EQS Group (DE) | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
03.06.2023 / 22:16 CET/CEST
Für... ► Artikel lesen | |
| 03.06.23 | EQS-DD: Vulcan Energy Resources Limited: Josephine Rachel Bush, Kauf | 2.565 | EQS Group (DE) | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
03.06.2023 / 22:14 CET/CEST
Für... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 432 |
| NVIDIA | 252 |
| DEUTSCHE BANK | 246 |
| BAYER | 214 |
| TESLA | 193 |
| RHEINMETALL | 184 |
| NEL | 178 |
| BYD | 172 |
| TUI | 161 |
| SUPER MICRO COMPUTER | 154 |
| BASF | 119 |
| MERCEDES-BENZ | 113 |
| AMAZON | 105 |
| RWE | 103 |
| VARTA | 102 |
| THYSSENKRUPP | 97 |
| MICROSOFT | 96 |
| AIXTRON SE | 94 |
| PLUG POWER | 94 |
| VOLKSWAGEN | 93 |
| XIAOMI | 92 |
| COMMERZBANK | 91 |
| DEUTSCHE LUFTHANSA | 88 |
| ALPHABET | 81 |
| DELIVERY HERO | 80 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
